# MERMAID-1 (NCT04385368)

> Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04385368
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: AstraZeneca
- Conditions: Carcinoma, Non-Small-Cell Lung
- Interventions: Durvalumab + SoC chemotherapy; Placebo + SoC chemotherapy
- Enrollment: 89
- Primary outcome: Disease-free Survival (DFS) in FAS (Using Investigator Assessments According to Response Evaluation Criteria in Solid Tumors 1.1 [RECIST 1.1])

## Indexed commentary on MERMAID-1 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=mermaid-1-nct04385368